VivoSeq
Other

Posterior Circulation

1

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Posterior Circulation is an early-stage landscape with 1 program across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

50/100

Pipeline

Programs by Phase

Preclinical1

Standard Pharmacological Treatment

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Terminated1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）
Terminated·—·Phase 4·NCT03506009·3 enrolled
Endovascular Treatment for Posterior Circulation Ischemic Stroke Post 1 Day （24 Hours） A Randomized Controlled Clinical Trial On Efficacy
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Preclinical·NCT07699029·244 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)